Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world characteristics and long-term efficacy/safety of a JAK inhibitor in severe alopecia areata
ChiCTR2500107789Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of baricitinib in alopecia areata, sponsored by West China Hospital of Sichuan University. Primary endpoint: Severity of Alopecia Tool (SALT). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on ChiCTR2500107789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107789.